Oncology Brothers: Practice-Changing Cancer Discussions
Oncology Brothers
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Episodes
Mentioned books
Oct 9, 2025 • 23min
How to Manage Thrombocytopenia (ITP, HIT, DIC, TTP) - Dr. Ronak Mistry
Welcome to the Oncology Brothers podcast! In this Challenging Cases episode, we take a deep dive into thrombocytopenia management—a common yet often perplexing topic in everyday hematology and oncology practice. We are joined by Dr. Ronak Mistry, hematologist at the University of Pennsylvania and co‑host of Fellows on Call, to walk through real‑world cases spanning ITP, anticoagulation with low platelets, and HIT.
We covered essential topics such as:
• Workup of thrombocytopenia and confirming the diagnosis of ITP
• First‑ and second‑line ITP therapy—steroids, IVIG, TPO receptor agonists, and splenectomy
• Managing anticoagulation in thrombocytopenic patients with cirrhosis and DVT
• Step‑by‑step approach to suspected HIT in the inpatient setting
• Rapid‑fire tips—transfusion thresholds, chemo‑related thrombocytopenia, and medication culprits
Whether you’re a hematologist, oncologist, or internal medicine resident, this episode is packed with case‑based teaching points, practical pearls, and the latest guidance from ASH and NCCN for non‑malignant hematology.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don’t forget to like, subscribe, and tune in for more challenging case discussions, treatment strategies, and expert insights from the world of hematology and oncology!
#Thrombocytopenia #HematologyPodcast #ITP #HIT #OncologyBrothers
Oct 6, 2025 • 26min
IMforte - Maintenance Lurbinectedin + Atezo FDA Approval for Extensive Small Cell Lung Cancer (SCLC)
In this episode of the Oncology Brothers podcast, we dive deep into the latest advancements in treating extensive stage small cell lung cancer (SCLC), focusing on the IMforte data and its clinical implications. We welcomed esteemed thoracic medical oncologists Drs. Isabel Preeshagul, Ticiana Leal, and Dr. Stephen Liu to discuss the findings presented at ASCO 2025 and World Lung 2025.
Key topics included:
• Overview of the IMforte study design and patient population
• The role of lurbinectedin and atezolizumab as maintenance therapy
• Significant improvements in progression-free survival (PFS) and overall survival (OS)
• Management of side effects and the importance of prophylactic growth factors
• Patient selection criteria for this new standard of care
With a focus on bridging the gap between community and academia, this episode provides valuable insights for medical oncologists and patients alike. Tune in to learn how these advancements are changing the landscape of SCLC treatment and improving patient outcomes.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other discussions on recent approvals, treatment algorithms, and challenging cases. We are the Oncology Brothers!
#IMforte #SCLC #Lurbinectedin #MaintenanceTherapy #ASCO2025 #OncologyBrothers #ES-SCLC
Oct 2, 2025 • 22min
Exploring the role of targeted radiopharmaceutical treatment in NETs
Welcome to the Oncology Brothers podcast! In this episode, we dive into the evolving landscape of neuroendocrine tumors (NETs) with guests Dr. Heloisa Soares, a medical oncologist, and Prof. Ken Herrmann, a nuclear medicine specialist. Together, we explored the role of Peptide Receptor Radionuclide Therapy (PRRT), imaging breakthroughs, and treatment sequencing to optimize outcomes for NET patients.
We cover essential topics such as:
• The role of Gallium-68 and Copper-64 DOTATATE PET imaging in diagnosis and planning
• Second-line standard use of PRRT and emerging data for first-line therapy
• Toxicities of PRRT—nausea, kidney toxicity, and bone marrow suppression
• Balancing sequencing strategies in well-differentiated and higher-grade tumors
• The critical role of multidisciplinary tumor boards in NET management
• Future directions including PRRT retreatment and ongoing clinical trials
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and tune in for more discussions on challenging cases, treatment algorithms, and expert insights in the field of oncology!
#NeuroendocrineTumors #NETs #PRRT #OncologyBrothers #CancerTreatment #NuclearMedicine
Sep 29, 2025 • 20min
Challenging Cases of Venous Thromboembolism (VTE) - Drs. Jennifer Vaughn & Nicolas Gallastegui
Welcome to the Oncology Brothers podcast! In this episode we we deep into the complexities of venous thromboembolism (VTE) with Drs. Jennifer Vaughn and Nicolas Gallastegui Crestani from The Ohio State University. Join us as we explore real-life VTE scenarios, discussing both provoked and unprovoked events, treatment durations, and cancer-associated cases. We cover essential topics such as:
• The workup for hypercoagulable states in young patients
• Long-term anticoagulation strategies for high-risk individuals
• The role of D-dimer and risk scores in decision-making
• Management of anticoagulation in patients with cancer undergoing treatment
• Rapid-fire scenarios including superficial vein thrombosis and portal vein thrombosis
Whether you're a healthcare professional or simply interested in the latest in oncology and hematology, this episode is packed with valuable insights and practical guidance.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and tune in for more discussions on challenging cases, treatment algorithms, and expert insights in the field of oncology!
#VTE #Anticoagulation #DOACs #Hematology #MedEd #OncologyBrothers #Thrombosis #Clots #DVT #PE
Sep 25, 2025 • 22min
How to Treat Cutaneous Melanoma in 2025 - Dr. Omid Hamid
In this episode of the Oncology Brothers podcast, we are joined by Dr. Omid Hamid, a melanoma specialist from Cedars-Sinai, to explore the current treatment landscape of cutaneous melanoma.
We covered a wide range of topics, including:
• The standard of care for early-stage melanoma, including wide local excision and sentinel lymph node evaluation.
• The role of adjuvant immunotherapy and BRAF/MEK inhibitors for high-risk patients.
• Insights into neoadjuvant treatment options for resectable disease, including recent trial data from NADINA and SWOG S1808.
• The importance of next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) in treatment planning and monitoring.
• The evolving treatment paradigm for metastatic melanoma, including the use of dual checkpoint inhibitors and BRAF/MEK inhibitors.
Join us as we discuss the latest advancements in melanoma treatment and the critical role of patient education and shared decision-making in oncology care.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more episodes on treatment algorithms, new FDA approvals, and conference highlights!
#Melanoma #Immunotherapy #BRAF #ctDNA #Neoadjuvant #OncologyBrothers
Sep 22, 2025 • 17min
Treatment Algorithm of Neuroendocrine Tumors (NET) in 2025 - Dr. Thor Halfdanarson
Welcome to the Oncology Brothers podcast! In this episode, we dive deep into the world of neuroendocrine tumors (NETs) with renowned expert Dr. Thor Halfdanarson from the Mayo Clinic.
Join us as we explore:
• The critical factors in diagnosing NETs, including origin, grade, histological features, and Ki-67.
• The importance of differentiating between functional and non-functional tumors and how this impacts treatment decisions.
• Dr. Halfdanarson's treatment paradigm, including the use of somatostatin analogs, radioligand therapy, and other targeted treatments.
• Monitoring strategies for patients, including the role of imaging and tumor markers like 5-HIAA and chromogranin.
• Insights into the evolving role of immunotherapy and next-generation sequencing in managing high-grade neuroendocrine carcinomas.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information and practical insights.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more discussions on cutting-edge cancer treatments and expert opinions in the field of oncology!
Sep 18, 2025 • 24min
WCLC 2025 Highlights: FLAURA2, HARMONi, ALCHEMIST with Dr. Balazs Halmos
Dr. Balazs Halmos, a thoracic medical oncologist at Montefiore Einstein Cancer Center, joins the discussion on crucial findings from the World Conference on Lung Cancer 2025. He highlights the FLAURA2 trial, showcasing how osimertinib combined with chemotherapy enhances survival for EGFR-positive non-small cell lung cancer patients. Halmos delves into the HARMONi trial's unexpected results with a bi-specific antibody and the significance of ctDNA. He wraps up with insights on crizotinib's role in ALK-positive cases and the evolving landscape of precision oncology.
Sep 11, 2025 • 25min
Treating and Managing Chronic Lymphocytic Leukemia (CLL) in 2025: Dr. Mazyar Shadman
Dr. Mazyar Shadman, a leading expert in lymphoid malignancies at Fred Hutch Cancer Center, discusses the future of Chronic Lymphocytic Leukemia (CLL) treatment. He emphasizes the importance of shared decision-making and explores the timing for initiating treatment. Key topics include the choice between time-limited venetoclax regimens and continuous BTK inhibitors, the significance of minimal residual disease (MRD), and innovative strategies for managing relapsed CLL, such as Pirtobrutinib and CAR-T therapies.
Aug 29, 2025 • 15min
Managing Side Effects of New Treatments for Small Cell Lung Cancer
Dr. Misty Shields, a medical oncologist at Indiana University specializing in small cell lung cancer, shares her insights on managing side effects from new treatments. She discusses the latest advancements from ASCO 2025, focusing on the treatment algorithm for patients with good performance status. Key points include common side effects of lurbinectedin and immunotherapy, strategies for managing hematologic toxicities, and the crucial role of supportive and palliative care in improving patient quality of life. Collaboration between community oncologists and academic centers is emphasized for optimal care.
Aug 25, 2025 • 13min
FDA Approval of Zongertinib for HER2 Mutated Non-Small Cell Lung Cancer (NSCLC) - Dr. Joshua Sabari
Dr. Joshua Sabari, a medical oncologist at NYU Langone Cancer Center, shares his expertise on the groundbreaking approval of Zongertinib for HER2-mutated non-small cell lung cancer. He discusses the prevalence of HER2 mutations, revealing key study findings with impressive response rates and progression-free survival data. The podcast dives into the management of side effects, particularly diarrhea, and compares Zongertinib with trastuzumab deruxtecan in treatment settings. Dr. Sabari also explores future directions for HER2-targeted therapies.
